Long-term response to deferiprone therapy in Asian Indians

Annals of Hematology

Volumn 89, Issue 2, 2010, Pages 135-140

  Panigrahi, Inusha ^a   Marwaha, Ram K ^a   Das, Rashmi R ^a   Trehan, Amita ^a   Bansal, Deepak ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Beta thalassemia major; Iron chelation; Iron overload; L1; Serum ferritin

Indexed keywords

ANALGESIC AGENT; ASUNRA; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DESIROX; FERRITIN; UNCLASSIFIED DRUG; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; ANKLE PAIN; ARTHRALGIA; ARTHROPATHY; ARTICLE; ASIAN; CHILD; CHRONIC DISEASE; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; IRON CHELATION; IRON OVERLOAD; KNEE PAIN; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; WRIST DISEASE; BLOOD; CHELATION THERAPY; CHEMICALLY INDUCED DISORDER; INDIA; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; ASIAN CONTINENTAL ANCESTRY GROUP; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; FEMALE; FERRITINS; HUMANS; INDIA; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; NEUTROPENIA; PYRIDONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 74049142066     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0797-4     Document Type: Article

References (29)

1. Olivieri NF, Brittenham GM (1997) Iron-chelating therapy and the treatment of thalassemia. Blood 89(3):739-755.
2. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR (2004) Complications of β-thalassemia major in North America. Blood 104(1):34-39.
3. Hider RC, Zhou T (2005) The design of orally active iron chelators. Ann N Y Acad Sci 1054:141-154.
4. Cappellini MD, Cohen A, Piga A et al (2005) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with {beta}-thalassemia. Blood 107:3455-3462.
5. Borgna-Pignatti C, Cappellini MD, De Stefano P et al (2005) Cardiac morbidity and mortality in deferoxamine or deferipronetreated patients with thalassemia major. Blood 107:3733-3737.
6. Pennell DJ, Berdoukas V, Karagiorga M et al (2005) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107:3738-3744.
7. Nisbet-Brown E, Olivieri NF, Giardina PJ et al (2003) Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose escalation trial. Lancet 361:1597-1602.
8. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F (2003) Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 102:1583-1587.
9. Hoffbrand AV, Cohen A, Hershko C (2003) Role of deferiprone in chelation therapy for transfusional iron overload. Blood 102:17-24.
10. Ceci A, Baiardi P, Felisi M et al (2002) The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 118:330-336.
11. Tondury P, Zimmermann A, Nielsen P, Hirt A (1998) Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol 101(3):413-415.
12. Al-Refaie FN, Hershko C, Hoffbrand AV et al (1995) Results of long-term deferiprone (L1) therapy: a report by the international study group on oral iron chelators. Br J Haematol 91:224-229.
13. Olivieri NF, Brittenham GM (1997) Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO)[abstract]. Blood (suppl 90):1161a.
14. Agarwal MB, Gupte SS, Viswanathan C et al (1992) Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassemia: Indian trial. Br J Haematol 82:460-466.
15. Olivieri NF, Brittenham GM, Matsui D et al (1995) Iron chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 332:918-922.
16. Hershko C, Hoffbrand AV, Kosaryan M et al (1994) Results of long-term deferiprone (L1) therapy. A report by the international study group on oral iron chelators [abstract]. Blood 84(suppl.):1012.
17. Olivieri NF, Sher GD, McKinnon JA et al (1994) The first prospective randomized trial of subcutaneous deferoxamine and the orally active iron chelating agent L1 [abstract]. Blood 84 (suppl.):1436.
18. Olivieri NF, Brittenham GM, McLaren CM et al (1998) Longterm safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 339(7):417-423.
19. Hoffbrand AV, Al-Refaie F, Davis B et al (1998) Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 91:295-300.
20. Lucas GN, Perera BJ, Fonseka EA et al (2002) Experience with the oral iron chelator deferiprone in transfusion-dependent children. Ceylon Med J 47(4):119-121.
21. Piga A, Gaglioti C, Fogliacco E, Tricta F (2003) Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 88:489-496.
22. Taher A, Aoun E, Sharara AI et al (2004) Five-year trial of deferiprone chelation therapy in thalassaemia major patients. Acta Haematol 112(4):179-183.
23. Ayyub M, Ali W, Anwar M et al (2005) Efficacy and adverseeffects of oral iron chelator deferiprone (l1, 1, 2-dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassemia major in Pakistan. J Ayub Med Coll Abbottabad 17(4):12-15.
24. Goel H, Girisha KM, Phadke SR (2008) Long-term efficacy of oral deferiprone in management of iron overload in beta thalassemia major. Hematology 13(2):77-82.
25. Berkovitch M, Laxer RM, Inman R et al (1994) Arthropathy in thalassemia patients receiving deferiprone. Lancet 343:1471-1472.
26. Cohen AR, Galanello R, Piga A et al (2000) Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 108:305-312.
27. Al-Refaie FN, Wonke B, Hoffbrand AV (1994) Deferiprone associated myelotoxicity. Eur J Haematol 53:298-301.
28. Hoffbrandt AV (1996) Oral iron chelation. Semin Hematol 33:1-8.
29. Olivieri NF (1996) Long-term therapy with deferiprone. Acta Haematologica 95:37-48.